AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26404954 — intervention group
Group type: EXPERIMENTAL
Intervention: Working memory training (experimental group)
Number of subjects: 28
Study 26404954 — intervention group
Group type: COMPARATOR
Intervention: Active control (control group)
Number of subjects: 28
Study 23706413 — intervention group
Group type: EXPERIMENTAL
Intervention: RYGB surgery (group C)
Number of subjects: 108
Study 23706413 — intervention group
Group type: COMPARATOR
Intervention: Usual care plus Exenatide (group B)
Number of subjects: 108
Study 23706413 — intervention group
Group type: COMPARATOR
Intervention: Usual care (group A)
Number of subjects: 108
Study 21369479 — intervention group
Group type: EXPERIMENTAL
Intervention: HA/CMC injection
Number of subjects: 80
Study 21369479 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study 19263035 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-bundle reconstruction
Number of subjects: 26
Study 19263035 — intervention group
Group type: COMPARATOR
Intervention: Double-bundle reconstruction
Number of subjects: 26
Study 17244147 — intervention group
Group type: EXPERIMENTAL
Intervention: Cast post and core system (Ni-Cr)
Number of subjects: 30
Study 17244147 — intervention group
Group type: COMPARATOR
Intervention: Fiber-reinforced resin posts (glass fiber: FRC Postec; quartz fiber: D.T. Light-Post)
Number of subjects: 30
Study 15673186 — intervention group
Group type: EXPERIMENTAL
Intervention: Thinking aloud
Number of subjects: 58
Study 15673186 — intervention group
Group type: COMPARATOR
Intervention: Silent condition
Number of subjects: 58
Study 15673186 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal protocols analysis
Number of subjects: 58
Study 15475635 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose hepatitis B vaccine (2 mcg) given intradermally
Number of subjects: 196
Study 15475635 — intervention group
Group type: COMPARATOR
Intervention: Standard dose hepatitis B vaccine (10 mcg) given intramuscularly
Number of subjects: 196
Study 10030554 — intervention group
Group type: EXPERIMENTAL
Intervention: Carteolol hydrochloride 1.0%
Number of subjects: 112
Study 10030554 — intervention group
Group type: COMPARATOR
Intervention: Timolol maleate 0.5%
Number of subjects: 112
Study 10030554 — intervention group
Group type: COMPARATOR
Intervention: Comparison between Carteolol and Timolol
Number of subjects: 112
Study 7577849 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestrinone (2.5 mg twice weekly)
Number of subjects: 269
Study 7577849 — intervention group
Group type: EXPERIMENTAL
Intervention: Danazol (200 mg twice daily)
Number of subjects: 269
Study 7577849 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 269
Study 2022705 — intervention group
Group type: EXPERIMENTAL
Intervention: hCG (Profasi; 2000 IU, im)
Number of subjects: 48
Study 2022705 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 2022705 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 48
Study 7049313 — intervention group
Group type: EXPERIMENTAL
Intervention: Rubber band ligation
Number of subjects: 80
Study 7049313 — intervention group
Group type: COMPARATOR
Intervention: Haemorrhoidectomy
Number of subjects: 80
Study 7049313 — intervention group
Group type: EXPERIMENTAL
Intervention: Rubber band ligation and haemorrhoidectomy
Number of subjects: 80
Study 28633702 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid preventive therapy (IPT)
Number of subjects: 2374
Study 28633702 — intervention group
Group type: COMPARATOR
Intervention: Placebo (non-IPT)
Number of subjects: 2374
Study 28633702 — intervention group
Group type: COMPARATOR
Intervention: MVA85A vaccine
Number of subjects: 2374
Study 28633702 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2374
Study 26154184 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle guidance technology (eZono)
Number of subjects: 100
Study 23397969 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-affirmation activities
Number of subjects: 0
Study 23397969 — intervention group
Group type: COMPARATOR
Intervention: Control activities
Number of subjects: 0
Study 23397969 — intervention group
Group type: COMPARATOR
Intervention: Non-affirmed Latino American students
Number of subjects: 0
Study 20211501 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidimensional exercise (twice a week for 3 months)
Number of subjects: 61
Study 20211501 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 61
Study 19584716 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-driven alert system
Number of subjects: 140
Study 19584716 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 140
Study 17962426 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose combination of 150 mg lamivudine, 300 mg zidovudine, and 200 mg nevirapine
Number of subjects: 64
Study 17962426 — intervention group
Group type: COMPARATOR
Intervention: Individual products (lamivudine, zidovudine, nevirapine)
Number of subjects: 64
Study 17962426 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose combination
Number of subjects: 64
Study 17962426 — intervention group
Group type: COMPARATOR
Intervention: Fixed-dose combination and individual products
Number of subjects: 64
Study 15078751 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirometry
Number of subjects: 3408
Study 15078751 — intervention group
Group type: COMPARATOR
Intervention: Questionnaire
Number of subjects: 3408
Study 11211891 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha 2b 3 MU tiw for 24 or 48 weeks plus ribavirin 1000‐1200 mg
Number of subjects: 912
Study 11211891 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 912
Study 9510317 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg mesalazine suppositories administered three times per day
Number of subjects: 58
Study 9510317 — intervention group
Group type: COMPARATOR
Intervention: 800 mg oral mesalazine tablets taken three times per day
Number of subjects: 58
Study 7802191 — intervention group
Group type: EXPERIMENTAL
Intervention: Oscillometric finger cuffs
Number of subjects: 41
Study 29587373 — intervention group
Group type: EXPERIMENTAL
Intervention: Deterministic algorithms
Number of subjects: 6
Study 29587373 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized algorithms
Number of subjects: 6
Study 29587373 — intervention group
Group type: EXPERIMENTAL
Intervention: Fastest deterministic algorithm
Number of subjects: 6
Study 26987935 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low-dose factor VIII prophylaxis (10 units kg(‐1) body weight on 2 days a week)
Number of subjects: 21
Study 26987935 — intervention group
Group type: COMPARATOR
Intervention: Episodic (On demand) factor concentrate in standard recommended doses
Number of subjects: 21
Study 26987935 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low-dose factor VIII prophylaxis
Number of subjects: 21
Study 26987935 — intervention group
Group type: COMPARATOR
Intervention: Episodic (On demand) factor concentrate
Number of subjects: 21
Study 25343394 — intervention group
Group type: EXPERIMENTAL
Intervention: TCR (Total Caries Removal)
Number of subjects: 51
Study 25343394 — intervention group
Group type: COMPARATOR
Intervention: PCR (Partial Caries Removal)
Number of subjects: 51
Study 25343394 — intervention group
Group type: EXPERIMENTAL
Intervention: TCR
Number of subjects: 51
Study 25343394 — intervention group
Group type: COMPARATOR
Intervention: PCR
Number of subjects: 51
Study 25343394 — intervention group
Group type: EXPERIMENTAL
Intervention: TCR and PCR
Number of subjects: 51
Study 23636649 — intervention group
Group type: EXPERIMENTAL
Intervention: Casually intervened home‐based exercise group (CIHE)
Number of subjects: 17
Study 23636649 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensely intervened home‐based exercise group (IIHE)
Number of subjects: 17
Study 20658586 — intervention group
Group type: EXPERIMENTAL
Intervention: Eculizumab treatment
Number of subjects: 195
Study 18971139 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol 400 microg
Number of subjects: 101
Study 18971139 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study 17161243 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel + eptifibatide
Number of subjects: 120
Study 17161243 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel alone
Number of subjects: 120
Study 12938046 — intervention group
Group type: EXPERIMENTAL
Intervention: IRES-3 questionnaire
Number of subjects: 1818
Study 10743876 — intervention group
Group type: EXPERIMENTAL
Intervention: Talk alone
Number of subjects: 256
Study 10743876 — intervention group
Group type: EXPERIMENTAL
Intervention: Talk to a validating confederate
Number of subjects: 256
Study 10743876 — intervention group
Group type: COMPARATOR
Intervention: No-talk control condition
Number of subjects: 256
Study 10743876 — intervention group
Group type: EXPERIMENTAL
Intervention: Talk to an invalidating confederate
Number of subjects: 256
Study 9361242 — intervention group
Group type: EXPERIMENTAL
Intervention: FK506
Number of subjects: 25
Study 9361242 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine
Number of subjects: 25
Study 1488696 — intervention group
Group type: EXPERIMENTAL
Intervention: Rice-powder salt solution (RPSS) - 30 g/l rice powder and 3.5 g/l salt
Number of subjects: 64
Study 1488696 — intervention group
Group type: COMPARATOR
Intervention: WHO recommended glucose electrolyte solution (WHO-ORS)
Number of subjects: 64
Study 1488696 — intervention group
Group type: COMPARATOR
Intervention: Glycine supplemented WHO-ORS (G-ORS)
Number of subjects: 64
Study 3566222 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysozyme in combination with antibiotics
Number of subjects: 175
Study 3566222 — intervention group
Group type: COMPARATOR
Intervention: Antibiotics without lysozyme
Number of subjects: 175
Study 31399916 — intervention group
Group type: EXPERIMENTAL
Intervention: CAPA-IVM
Number of subjects: 40
Study 31399916 — intervention group
Group type: COMPARATOR
Intervention: STD IVM
Number of subjects: 40
Study 30203756 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan combined with hydrochlorothiazide
Number of subjects: 160
Study 30203756 — intervention group
Group type: COMPARATOR
Intervention: Valsartan (Control)
Number of subjects: 160
Study 26833752 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 U/mL heparin (low dose)
Number of subjects: 100
Study 26833752 — intervention group
Group type: COMPARATOR
Intervention: 5000 U/mL heparin (high dose)
Number of subjects: 100
Study 24745013 — intervention group
Group type: EXPERIMENTAL
Intervention: Tension-free vaginal tape (TVT)
Number of subjects: 527
Study 24745013 — intervention group
Group type: EXPERIMENTAL
Intervention: Transobturator tape (TOT)
Number of subjects: 527
Study 24745013 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified transobturator tape (mTOT)
Number of subjects: 527
Study 24745013 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean surgery time for TVT
Number of subjects: 527
Study 24745013 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean surgery time for TOT
Number of subjects: 527
Study 24745013 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean surgery time for mTOT
Number of subjects: 527
Study 24745013 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean hospitalization time
Number of subjects: 527
Study 24745013 — intervention group
Group type: COMPARATOR
Intervention: Mean catheter maintenance time
Number of subjects: 527
Study 22921260 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabilone 1-4 mg/day (n=13)
Number of subjects: 37
Study 22921260 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=13)
Number of subjects: 37
Study 20805256 — intervention group
Group type: COMPARATOR
Intervention: Continuous antidepressant use in the placebo arm
Number of subjects: 0
Study 20805256 — intervention group
Group type: COMPARATOR
Intervention: Continuous antidepressant use in the lifestyle arm
Number of subjects: 0
Study 20805256 — intervention group
Group type: COMPARATOR
Intervention: Continuous antidepressant use in the metformin arm
Number of subjects: 0
Study 19100930 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blocker therapy
Number of subjects: 1000
Study 19100930 — intervention group
Group type: EXPERIMENTAL
Intervention: Complications
Number of subjects: 1000
Study 16197668 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclobenzaprine 5 mg TID for 7 days (CYC5)
Number of subjects: 867
Study 16197668 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclobenzaprine 5 mg TID plus Ibuprofen 400 mg TID (CYC5/IBU400)
Number of subjects: 867
Study 16197668 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclobenzaprine 5 mg TID plus Ibuprofen 800 mg TID (CYC5/IBU800)
Number of subjects: 867
Study 16197668 — intervention group
Group type: COMPARATOR
Intervention: All treatments (CYC5, CYC5/IBU400, CYC5/IBU800)
Number of subjects: 867
Study 12114340 — intervention group
Group type: EXPERIMENTAL
Intervention: Respitin (60 mg/kg once weekly)
Number of subjects: 26
Study 12114340 — intervention group
Group type: COMPARATOR
Intervention: Prolastin (60 mg/kg once weekly)
Number of subjects: 26
Study 12114340 — intervention group
Group type: EXPERIMENTAL
Intervention: Respitin
Number of subjects: 26
Study 12114340 — intervention group
Group type: COMPARATOR
Intervention: Respitin and Prolastin
Number of subjects: 26
Study 10439755 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan 40 mg orally with premedication, then 40 mg three times per day for 2 days
Number of subjects: 50
Study 10439755 — intervention group
Group type: COMPARATOR
Intervention: Placebo at identical times
Number of subjects: 50
Study 8849208 — intervention group
Group type: EXPERIMENTAL
Intervention: Demiquet (male mass. demispan-2)
Number of subjects: 394
Study 8849208 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindex (female mass. demispan-1)
Number of subjects: 394
Study 8849208 — intervention group
Group type: EXPERIMENTAL
Intervention: Demispan measurement
Number of subjects: 394
Study 2189976 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants with BPD
Number of subjects: 223
Study 2189976 — intervention group
Group type: COMPARATOR
Intervention: Control infants
Number of subjects: 223
Study 760920 — intervention group
Group type: EXPERIMENTAL
Intervention: isomers of flupenthixol
Number of subjects: 45
Study 760920 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 45
Study 31944519 — intervention group
Group type: COMPARATOR
Intervention: 20% glycolic acid peel
Number of subjects: 90
Study 31944519 — intervention group
Group type: COMPARATOR
Intervention: 15% lactic acid peel
Number of subjects: 90
Study 31944519 — intervention group
Group type: COMPARATOR
Intervention: 12% ferulic acid peel
Number of subjects: 90
Study 30571288 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance exercise training (TR)
Number of subjects: 19
Study 30571288 — intervention group
Group type: COMPARATOR
Intervention: Nonexercising control group (CON)
Number of subjects: 19
Study 28245628 — intervention group
Group type: EXPERIMENTAL
Intervention: FOS (8 g/day)
Number of subjects: 84
Study 28245628 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sucrose)
Number of subjects: 84
Study 24720551 — intervention group
Group type: EXPERIMENTAL
Intervention: Mavrilimumab (10-100 mg)
Number of subjects: 51
Study 24720551 — intervention group
Group type: EXPERIMENTAL
Intervention: Mavrilimumab (30 mg and 100 mg)
Number of subjects: 51
Study 24720551 — intervention group
Group type: EXPERIMENTAL
Intervention: Mavrilimumab (100 mg)
Number of subjects: 51
Study 24720551 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 24410973 — intervention group
Group type: EXPERIMENTAL
Intervention: Listening to Mozart K.448 daily before bedtime for at least six months
Number of subjects: 46
Study 24410973 — intervention group
Group type: EXPERIMENTAL
Intervention: Listening to Mozart K.448
Number of subjects: 46
Study 24410973 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 46
Study 23016822 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT)
Number of subjects: 82
Study 23016822 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 82
Study 19220753 — intervention group
Group type: EXPERIMENTAL
Intervention: STW 5
Number of subjects: 103
Study 19220753 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study 18077808 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 435
Study 18077808 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 435
Study 16338555 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal hinge
Number of subjects: 47
Study 16338555 — intervention group
Group type: COMPARATOR
Intervention: Superior hinge
Number of subjects: 47
Study 12381742 — intervention group
Group type: EXPERIMENTAL
Intervention: L-tyrosine (25 mg/kg body wt)
Number of subjects: 9
Study 12381742 — intervention group
Group type: EXPERIMENTAL
Intervention: Polydextrose (70 g/l) and L-tyrosine (25 mg/kg body wt) (CHO+Tyr)
Number of subjects: 9
Study 12381742 — intervention group
Group type: COMPARATOR
Intervention: Polydextrose (70 g/l) (CHO)
Number of subjects: 9
Study 12381742 — intervention group
Group type: COMPARATOR
Intervention: Water sweetened with aspartame (placebo) (Pla)
Number of subjects: 9
Study 9583332 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Treatment (CBT)
Number of subjects: 1726
Study 9583332 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy (MET)
Number of subjects: 1726
Study 9583332 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-Step Facilitation (TSF)
Number of subjects: 1726
Study 9583332 — intervention group
Group type: COMPARATOR
Intervention: Control (nonstudy treatments)
Number of subjects: 1726
Study 8674482 — intervention group
Group type: EXPERIMENTAL
Intervention: Wipe sampling
Number of subjects: 216
Study 8674482 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacuum sampling
Number of subjects: 216
Study 8674482 — intervention group
Group type: EXPERIMENTAL
Intervention: Wipe samples correlation analysis
Number of subjects: 216
Study 8674482 — intervention group
Group type: EXPERIMENTAL
Intervention: General findings
Number of subjects: 216
Study 1975496 — intervention group
Group type: EXPERIMENTAL
Intervention: Mequitazine
Number of subjects: 20
Study 1975496 — intervention group
Group type: COMPARATOR
Intervention: Chlorpheniramine
Number of subjects: 20
Study 1975496 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 362213 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin and glucose
Number of subjects: 0
Study 362213 — intervention group
Group type: COMPARATOR
Intervention: Glucose alone
Number of subjects: 0
Study 362213 — intervention group
Group type: COMPARATOR
Intervention: Regimen containing mainly fat (intralipid and sorbitol)
Number of subjects: 0
Study 362213 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin
Number of subjects: 0
Study 362213 — intervention group
Group type: COMPARATOR
Intervention: No intervention (noncatabolic patients)
Number of subjects: 0
Study 31886744 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin Converting Enzyme inhibitors (ACEis)
Number of subjects: 0
Study 31886744 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin Receptor Blockers (ARBs)
Number of subjects: 0
Study 31886744 — intervention group
Group type: EXPERIMENTAL
Intervention: RAS molecules (Angiotensin II, Ang-(1-7))
Number of subjects: 0
Study 31886744 — intervention group
Group type: EXPERIMENTAL
Intervention: RAS targeting drugs (ACEis and ARBs)
Number of subjects: 0
Study 30107536 — intervention group
Group type: EXPERIMENTAL
Intervention: α‐Cyclodextrin (α‐CD) 2 g per meal for 2 days
Number of subjects: 8
Study 30107536 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 30107536 — intervention group
Group type: EXPERIMENTAL
Intervention: α‐Cyclodextrin (α‐CD)
Number of subjects: 8
Study 26267851 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS for 30 minutes and task oriented exercises
Number of subjects: 30
Study 26267851 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS for 60 minutes and task oriented exercises
Number of subjects: 30
Study 26267851 — intervention group
Group type: COMPARATOR
Intervention: Task oriented exercises
Number of subjects: 30
Study 24106806 — intervention group
Group type: EXPERIMENTAL
Intervention: Target-controlled infusion (TCI) with propofol
Number of subjects: 220
Study 24106806 — intervention group
Group type: COMPARATOR
Intervention: Intermittent bolus of cocktail regimen (midazolam, alfentanil, and propofol)
Number of subjects: 220
Study 22728905 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential nephron blockade (group 1, n = 85)
Number of subjects: 167
Study 22728905 — intervention group
Group type: COMPARATOR
Intervention: Sequential renin-angiotensin system blockade (group 2, n = 82)
Number of subjects: 167
Study 22728905 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential nephron blockade (group 1)
Number of subjects: 167
Study 22728905 — intervention group
Group type: COMPARATOR
Intervention: Sequential renin-angiotensin system blockade (group 2)
Number of subjects: 167
Study 20625110 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote home monitoring (HM)
Number of subjects: 1339
Study 20625110 — intervention group
Group type: COMPARATOR
Intervention: Conventional follow-up
Number of subjects: 1339
Study 18345713 — intervention group
Group type: EXPERIMENTAL
Intervention: FazaClo (clozapine orally disintegrating tablets) 100 mg
Number of subjects: 36
Study 18345713 — intervention group
Group type: COMPARATOR
Intervention: Clozaril (clozapine standard oral tablets) 100 mg
Number of subjects: 36
Study 16485521 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild leg exercise (Ex)
Number of subjects: 8
Study 16485521 — intervention group
Group type: COMPARATOR
Intervention: Seated at rest (R)
Number of subjects: 8
Study 12430146 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic Therapy (PDT) using a KTP-dye module laser at 630 nm with a primary fluence rate of 100 mW cm(‐2)
Number of subjects: 15
Study 12430146 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic Therapy (PDT)
Number of subjects: 15
Study 11079734 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergen-reduced dietary intervention (breastfeeding and moderate whey hydrolysate formula, pHF)
Number of subjects: 1130
Study 11079734 — intervention group
Group type: COMPARATOR
Intervention: Control group (infant formula with unhydrolysed proteins, IF)
Number of subjects: 1130